141 related articles for article (PubMed ID: 29534999)
41. Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor.
Cattaneo M; Lecchi A; Ohno M; Joshi BV; Besada P; Tchilibon S; Lombardi R; Bischofberger N; Harden TK; Jacobson KA
Biochem Pharmacol; 2004 Nov; 68(10):1995-2002. PubMed ID: 15476670
[TBL] [Abstract][Full Text] [Related]
42. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice.
Hechler B; Zhang Y; Eckly A; Cazenave JP; Gachet C; Ravid K
J Thromb Haemost; 2003 Jan; 1(1):155-63. PubMed ID: 12871553
[TBL] [Abstract][Full Text] [Related]
43. ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets.
Fälker K; Lange D; Presek P
Thromb Haemost; 2004 Jul; 92(1):114-23. PubMed ID: 15213852
[TBL] [Abstract][Full Text] [Related]
44. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation.
Léon C; Vial C; Gachet C; Ohlmann P; Hechler B; Cazenave JP; Lecchi A; Cattaneo M
Thromb Haemost; 1999 May; 81(5):775-81. PubMed ID: 10365753
[TBL] [Abstract][Full Text] [Related]
45. ADP-induced platelet shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation.
Wilde JI; Retzer M; Siess W; Watson SP
Platelets; 2000 Aug; 11(5):286-95. PubMed ID: 11030463
[TBL] [Abstract][Full Text] [Related]
46. [PI3-kinase mediates activity of RhoA and interaction of RhoA with mDia1 in thrombin-induced platelet aggregation].
Gao GX; Dong HJ; Gu HT; Gao Y; Pan YZ; Yang Y; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1555-9. PubMed ID: 20030946
[TBL] [Abstract][Full Text] [Related]
47. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation.
Chang H; Yanachkov IB; Dix EJ; Li YF; Barnard MR; Wright GE; Michelson AD; Frelinger AL
J Thromb Haemost; 2012 Dec; 10(12):2573-80. PubMed ID: 23083103
[TBL] [Abstract][Full Text] [Related]
48. P2Y1 receptor inhibits GABA transport through a calcium signalling-dependent mechanism in rat cortical astrocytes.
Jacob PF; Vaz SH; Ribeiro JA; Sebastião AM
Glia; 2014 Aug; 62(8):1211-26. PubMed ID: 24733747
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the aggregation responses of camel platelets.
Al Ghumlas AK; Gader AG
Vet Clin Pathol; 2013 Sep; 42(3):307-13. PubMed ID: 23919654
[TBL] [Abstract][Full Text] [Related]
50. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.
Park HS; Hourani SM
Br J Pharmacol; 1999 Jul; 127(6):1359-66. PubMed ID: 10455285
[TBL] [Abstract][Full Text] [Related]
51. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
52. 2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents.
Pi Z; Sutton J; Lloyd J; Hua J; Price L; Wu Q; Chang M; Zheng J; Rehfuss R; Huang CS; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2013 Jul; 23(14):4206-9. PubMed ID: 23743287
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of ZL55 cell proliferation by ADP via PKC-dependent signalling pathway.
Muscella A; Cossa LG; Vetrugno C; Antonaci G; Marsigliante S
J Cell Physiol; 2018 Mar; 233(3):2526-2536. PubMed ID: 28777435
[TBL] [Abstract][Full Text] [Related]
54. Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets.
Rolf MG; Mahaut-Smith MP
Thromb Haemost; 2002 Sep; 88(3):495-502. PubMed ID: 12353081
[TBL] [Abstract][Full Text] [Related]
55. Investigation of cyclooxygenase and signaling pathways involved in human platelet aggregation mediated by synergistic interaction of various agonists.
Khan N; Farooq AD; Sadek B
Drug Des Devel Ther; 2015; 9():3497-506. PubMed ID: 26185418
[TBL] [Abstract][Full Text] [Related]
56. Rac1 plays a role in CXCL12 but not CCL3-induced chemotaxis and Rac1 GEF inhibitor NSC23766 has off target effects on CXCR4.
Mills SC; Howell L; Beekman A; Stokes L; Mueller A
Cell Signal; 2018 Jan; 42():88-96. PubMed ID: 29050986
[TBL] [Abstract][Full Text] [Related]
57. Antiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphate.
Chang H; Yanachkov IB; Dix EJ; Yanachkova M; Li Y; Barnard MR; Wright GE; Michelson AD; Frelinger AL
PLoS One; 2014; 9(4):e94780. PubMed ID: 24722456
[TBL] [Abstract][Full Text] [Related]
58. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway.
Kiian I; Tkachuk N; Haller H; Dumler I
Thromb Haemost; 2003 May; 89(5):904-14. PubMed ID: 12719789
[TBL] [Abstract][Full Text] [Related]
59. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
60. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function.
Kaneider NC; Egger P; Dunzendorfer S; Wiedermann CJ
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):1029-35. PubMed ID: 12067916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
